



Markets
/
Stocks
/
nasdaq-onc
/

Beigene Ltd

ONC

View Detailed Chart

259.810USD

+10.039+4.02%

Close 04/30, 16:00（ET）Quotes delayed by 15 min

25.43BMarket Cap

LossP/E TTM



Beigene Ltd

259.810

+10.039+4.02%

Company

Intraday

30m

Today

+4.02%

5 Days

+4.29%

1 Month

+6.39%

6 Months

+28.21%

Year to Date

+40.66%

1 Year

+68.77%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 22 analysts

BUY

Current Rating

314.767

Target Price

26.02%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

561

Total

Median

Average

Company name

Ratings

Analysts

Beigene Ltd

ONC

CRISPR Therapeutics AG

CRSP

Regeneron Pharmaceuticals Inc

REGN

Intellia Therapeutics Inc

NTLA

Moderna Inc

MRNA

Exact Sciences Corp

EXAS

...

112

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(4)

Buy(7)

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

2.254

Buy

RSI(14)

56.808

Neutral

STOCH(KDJ)(9,3,3)

68.690

Neutral

ATR(14)

12.623

Low Volatility

CCI(14)

59.336

Neutral

Williams %R

16.071

Overbought

TRIX(12,20)

0.297

Sell

StochRSI(14)

33.327

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

249.884

Buy

MA10

242.937

Buy

MA20

239.786

Buy

MA50

226.195

Buy

MA100

210.282

Buy

MA200

197.014

Buy

News

More news coming soon, stay tuned...

Company

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Company codeONC

CompanyBeigene Ltd

CEOMr. John Victor Oyler

Websitehttps://www.beigene.com/